Background 65 Genome-wide association studies have identified multiple genomic loci associated with coronary artery 66 disease, but most are common variants in non-coding regions that provide limited information on causal 67 genes and etiology of the disease. To better understand etiological pathways that might lead to discovery 131 Houston (21); SHIP was called in Illumina GenomeStudio using the CHARGE Consortium joint calling 132 cluster file; GeneSTAR used the Illumina GenomeStudio and zCall software (22); and WGHS data was 133 called using the Illumina BeadStudio v.3.3. Variant quality control (QC) was performed centrally (21) 134 and by the individual studies, including checking concordance with previous GWAS data, and excluding 135 participants with missing >5% genotypes, population clustering outliers, individuals with high inbreeding 136 coefficients or heterozygote rates, gender mismatches, duplicated pairs, and unexpectedly high proportion 137 of identity-by-descent sharing for family studies.
Introduction 90
Coronary heart disease (CHD) is a leading cause of morbidity and mortality worldwide, 91 accounting for one of every seven deaths in the United States in 2016.
(1) In addition to major modifiable 92 risk factors such as dyslipidemia, hypertension, diabetes, and cigarette smoking (2), genetic susceptibility 93 to CHD has also been investigated extensively through family-based studies, candidate gene studies, and 94 more recently genome-wide association studies (GWAS). (3-9) With progressively expanded sample sizes 95 in recent GWAS, at least 160 loci have been associated with the risk of coronary artery disease. (10-13)
96
Most of these loci are represented by common variants located in noncoding regions, resulting in limited 97 implications for causal genes and etiological pathways. Further, while most available data are derived 98 from genome-wide analysis of prevalent CHD, data are sparse from prospective studies of incident 99 cardiovascular events in populations free of baseline cardiovascular disease.
100
Low-frequency and rare coding sequence variations across the genome have been investigated in 101 studies of cardiovascular disease risk factors (14) (15) (16) (17) (18) , with the goal of better understanding the etiology of 102 these risk factors and to advance the discovery of the treatment and prevention of diseases. (19) We 103 previously published the results from a prospective analysis of CHD among individuals of European 104 ancestry from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
105
Consortium, and identified low-frequency and common variants associated with incident CHD. (20)
106
In this current study of individuals of European ancestry, we implemented both a cross-sectional 107 and prospective study design in the setting of the CHARGE Consortium to examine the association 108 between genetic variants and the risk of prevalent and incident myocardial infarction (MI) and CHD.
109
Study of incident cardiovascular events is enabled by the rigorous prospective design of population 110 cohorts contributing to the CHARGE Consortium. We also investigated whether these genetic variants are 111 associated with all-cause mortality after incident MI and CHD.
112 113 all-cause mortality. SeqMeta was used both at the study-specific analysis and meta-analysis levels. (32)
Materials and Methods

168
All study-specific analyses (single variant and gene-based tests) were adjusted for cohort-specific design 169 variables (e.g. study sites, family structure) and for population substructure using principal components as 170 needed. We applied a Bonferroni corrected threshold to determine statistical significance in each analysis 171 as described below.
173
Results
174
Prevalent MI and CHD association 175 A total of 27,349 participants of European ancestry from seven cohorts including 1831 prevalent 176 MI cases (6.7%) and 2518 prevalent CHD cases (9.2%) were used in the meta-analyses of prevalent 177 events (S1 Table) . We examined individually a total of 36,406 variants, combining both low-frequency 178 and common variants (MAF ≥ 1%), across all autosomal chromosomes corresponding to a Bonferroni 179 corrected significance threshold of P=1.37 × 10 -6 . A low-frequency (MAF=1.64%) intronic variant 180 (rs988583) in the phospholipase C like 1 gene (PLCL1) was significantly associated with prevalent MI 181 (P=7.12 × 10 -7 ; OR=1.80, 95% confidence interval=1.43 to 2.27; Table 1 ). Three common variants were 182 significantly associated with prevalent CHD: rs9349379 in PHACTR1 and rs1333048 and rs4977574 in 183 the 9p21 region (Table 1) . 185 *Chromosome and nucleotide positions are based on genome build GRCh37.
186
In the gene-based burden tests, we analyzed 16,628 autosomal genes that contained functional 187 low-frequency or rare variants with MAF < 5% and with a cumulative minor allele count (cMAC) ≥ 5;
188 therefore, the Bonferroni corrected p-value threshold was P=3.01 × 10 -6 . The transmembrane serine 189 protease 5 gene (TMPRSS5) on chromosome 11, containing nine nonsynonymous rare variants (S2 190  Table) , was significantly associated with prevalent MI (P=2.59 × 10 -6 , OR=3.00, 95% confidence 191 interval: 1.90, 4.73; Table 2 ). The low-density lipoprotein receptor class A domain containing 1 gene 192 (LDLRAD1) on chromosome 1 contained seven rare variants (S2 Table) and was significantly associated 193 with prevalent CHD (P=1.30 × 10 -6 , OR=4.48, 95% confidence interval: 2.44, 8.23; and contained 12 nonsynonymous and one splice-site rare variants (S4 Table) . No genes were 218 significantly associated with incident MI using SKAT. For the gene-based analyses of incident CHD, 219 16,620 genes were evaluated and the Bonferroni significance levels was P=3.01 × 10 -6 . Angiopoietin-220 like 4 (ANGPTL4) on chromosome 19 was significantly associated with incident CHD using SKAT
221
(P=1.29 × 10 -6 ; Table 4 ) and contained 10 variants (S4 Table) , and no gene was significantly associated 222 using the burden test. 
Post MI and CHD mortality analysis 230
Among the 3,751 MI and CHD cases from six cohorts that contributed to the analysis of all-cause 231 mortality, there were 1,860 all-cause deaths over a mean 10.9 years of follow-up (S5 Table) . We Table) . While these loci were significantly associated with prevalent and incident MI or CHD events, 238 only the 9p21 common variants were nominally associated with all-cause mortality (P < 0.05). The 9p21
239 variants that were associated with reduced risk of prevalent CHD (rs1333048 and rs4977574; Table 1 ),
240
and with increased risk of incident MI (rs1333048, rs4977574, rs10757278, and rs1333049; Table 3) 241 were all associated with modestly reduced risk of all-cause mortality (S6 Table) .
243
Discussion
244
Our study evaluated genetic susceptibility to MI and CHD in cross-sectional and prospective 245 settings among individuals of European ancestry. We confirmed several previously reported loci and newly identified one low-frequency variant and three genes harboring low-frequency and rare coding 247 variants that warrant investigation in future studies.
248
Single variant analysis of prevalent cardiovascular outcomes revealed a low-frequency 249 (MAF=1.64%) intronic variant, rs988583, in PLCL1 significantly associated with increased risk of MI 250 (P=7.12 × 10 -7 ). In silico replication was conducted by a look up of rs988583 and its association with 
261
A burden test aggregating low-frequency and rare coding variants in genes showed a significant 262 positive association between TMPRSS5 and prevalent MI (P=2.59 × 10 -6 ) and LDLRAD1 and prevalent 263 CHD (P=1.30 × 10 -6 ), and a significant protective association between RC3H2 and incident MI (P=2.99 × 264 10 -6 ). A significant association between ANGPTL4 and incident CHD was identified using SKAT (P=1.29 × 10 -6 Tables 1 and 3) , supporting the notion that low-frequency and rare variants may have a more substantial 285 impact on disease risk.
265
286
Although there was no statistically significant result found for all-cause mortality after MI or 287 CHD, after accounting for multiple testing, the protective direction of effect for many of our mortality 288 results suggests that genetic variants might contribute differently in various stages of disease 289 manifestation. Specifically, our results highlight differences in the direction of effect for common variants 290 at the 9p21 locus associated with decreased risk of prevalent CHD, increased risk of incident MI, and a 291 nominally significant reduced risk of all cause-mortality following a cardiovascular event. Generally, the 292 loci identified for prevalent disease were not the same as those identified for incident disease, as has been 293 observed in previous studies. (9) Indeed, comparison of prevalent and incident findings (S6 Table) shows 294 that the single variant (PLCL1 locus) and gene-based (TMPRSS5 locus) results for prevalent MI were not 295 significantly associated with incident MI, and the direction of effects were consistent for PLCL1 but not 296 TMPRSS5. Similarly, the significant gene, LDLRAD1, identified for increased risk of prevalent CHD was 297 not significantly associated with incident CHD, but the direction of effect was consistent. The RC3H2 gene, which showed an inverse association with incident MI, was not significantly associated with 299 prevalent MI and it exhibited an opposite direction of effect. A possible explanation for these observed 300 differences is that genetic studies of cardiovascular diseases are usually conducted with the cross-301 sectional study design, which has the potential to oversample participants with longer post-event survival 302 (42) and the results do not always replicate in the prospective studies for disease onset and vice versa. (9)
303
Given the limited statistical power of our findings for post-event survival, our study supports the need for 304 substantially larger well-phenotyped cohorts to differentiate effects of variants associated with CHD from 305 post-event mortality.
306
An advantage of this study is that within the setting of the CHARGE Consortium we are able to 307 evaluate and make comparisons between cross-sectional and prospective study designs, and to investigate 308 all-cause mortality following cardiovascular events. 
387
The Study of Health in Pomerania (SHIP) and SHIP-TREND both represent population-based studies. 
